With only 1 slide of a tumor section, an analysis of multiple tumor markers can be performed. The technique may help predict response to immunotherapy, which typically evokes responses in only a small group of patients.
Resistance to therapy through adaptation poses a major hurdle for cancer therapy. Bioengineers addressed this by creating a single nanoparticle that comprises a synergistic drug pair that shuts down mechanisms of resistance to a degree that has not been previously achieved.
A single dose and a beam of light can kill up to 95% of cancer cells in 2 hours, according to preclinical research on a novel approach to tumor resection. Photodynamic cancer therapy may be a treatment option for people whose tumors are inoperable or hard-to-reach.
A widely prescribed pain/anti-inflammatory medication reduced the growth of neurofibromatosis type 2 tumors in mice and in cell cultures, suggesting that the drug could reduce tumor growth in some cancers.
Tumors of varied types of genetically defined cancer were significantly reduced by the drug LOXO-101, according to phase 1 study results.
Gene therapy with a T cell receptor targeting a single cancer-specific point mutation is being used to eradicate large solid tumors.
Potential Drug Targets Are Identified With Finding That Genes in the Ly6 Gene Family Drive Tumorigenesis and Poor PrognosisFebruary 25, 2016
Lower patient survival and worse clinical outcomes across a variety of cancer types were correlated with increased expression of 4 genes in the Ly6 gene family. These findings came from an analysis of 130 gene expression studies from 10 solid cancers.
Analyzing tumor DNA fragments in the bloodstream, known as circulating tumor DNA (ctDNA), may offer a more complete view of a patient's cancer from a molecular perspective.
Optical probes that make cancer cells glow and improve surgical tumor removal are in phase I and II clinical trials in humans. The probes could be commonplace in the next 5 to 10 years, hypothesize the researchers.
A new injectable agent causes cancer cells in a tumor to fluoresce, potentially enabling surgeons to locate and remove all of a cancerous tumor on the first attempt.
Extra biopsies performed solely to study the pharmacodynamics of a new anticancer drug have no impact on subsequent drug development or on how physicians use these new drugs to treat future patients.
Genetic analyses and other tests performed by both researchers and physicians can be significantly skewed when normal cells, especially immune cells, are intermixed with cancerous cells in a tissue sample.
A novel genetic driver analysis of matched breast cancer primary tumors and multiorgan metastases suggests that most genetic drivers in a single tumor are based on DNA copy number variants (CNV), are established early, and are maintained in metastases. These findings were presented at the 2015 San Antonio Breast Cancer Symposium.
The size of a surgically removed tumor is generally thought to relate to the risk of metastasis; however, tumor cells metastasize at different times therefore the rate of spread is difficult to assess. A mathematical model was developed to calculate the relationship between tumor size and the relative risk of recurrence after surgery.
An FDA-approved, magnetic nanoparticle and MRI identifies tumors most likely to respond to drugs delivered via nanoparticles.
A new study has found an additional mechanism explaining how EGFR, a molecule long linked to cancer progression appears, to seed the body with metastatic cells long before doctors would typically detect a primary tumor.
A new laser-based microscope technology may help surgeons see the difference between tumor tissue and normal brain tissue in real-time.
Adult survivors of childhood brain tumors have lower working memory performance compared with healthy adults, according to research from Georgia State University and Emory University, in Atlanta.
A new surgical tool that uses light to ensure surgeons removed all of a cancerous tumor was found to correlate well with traditional pathologists' diagnoses, according to a clinical study showing that the tool could soon enable reliable, real-time surgical guidance.
A new study of the impact of exercise in models of breast cancer in mice has shown the benefits of exercise on the function of blood vessels around tumors.
A recent study provides a comprehensive analysis of the molecular alterations at work in phyllodes tumors, a rare type of breast tumor.
Patients with B-cell non-Hodgkin lymphomas and advanced solid tumors have responded to a new drug that is being tested for the first time in humans in a phase I clinical trial.
A novel medical-imaging technology, TexRAD, which analyzes the texture of tumors, has been shown in trials to enable early diagnosis of colorectal cancer in patients not responding to the standard cancer therapy better than other available tumor markers.
Two engineering researchers have challenged a commonly held idea about tumor ablation.
Cytokine therapy enhances the activity of natural killer (NK) cells against tumors that lack the cell surface protein known as MHC class I, according to new research.
JAK inhibitors have been found to halt tumor growth in colorectal cancer with a certain genetic mutation, according to a new study.
Scientists have known for decades that cancer can be caused by genetic mutations, but more recently they have discovered that chemical modifications of a gene can also contribute to cancer.
Deep within most tumors lie areas that remain untouched by chemotherapy and radiation. These areas lack the blood and oxygen needed for traditional therapies to work, but provide the perfect target for a new cancer treatment.
Clinical trials have begun for PFK-158, a small-molecule therapeutic candidate that inactivates a novel cancer metabolism target never before examined in human clinical trials.
- Novel Colonoscopy Prep Is Poised to Improve Screening Rates for Colon Cancer
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Study Suggests More Men With Prostate Cancer Would Choose Active Surveillance if it Were Offered
- The Bounty of Failure: A Well-Versed Nursing Experience
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- POLST Programs Can Benefit from the Relationship Between Patients and Nurse Practitioners
- Hydroxyurea May Improve Kidney Function in PV-Associated Nephrotic Syndrome
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|